ROB FAUBER, NOÉMIE HEULAND, SHIVANI KAK. I'm Shivani Kak, Head of Investor Relations. In accordance with the act, I also direct your attention to the Management's Discussion and Analysis section and ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary ...